# ACAAI: Considerable delay seen from Rx to approval for children's biologics

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-acaai-considerable-delay-rx-children.html) · 2026-11-16 · Medicine
Page: https://themorning.science/story/acaai-considerable-delay-seen-from-rx-to-approval-for-children-s-biologics-626fcfbb8f550411
Kind: research · Impact: medium

## In brief

- A study presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) found a considerable delay between prescribing a biologic therapy and final approval for pediatric patients.
- Almost 40% of prescriptions that require prior authorization (PA) are denied, according to the study.

## Why it matters

Children who need biologic therapy may face long waits and frequent denials before treatment starts, which can delay care for their conditions.

## Coverage

- [ACAAI: Considerable delay seen from Rx to approval for children's biologics](https://medicalxpress.com/news/2026-11-acaai-considerable-delay-rx-children.html) — Medical Xpress - latest medical and health news stories, 2026-11-16

Tags: pediatrics, biologics, prior authorization, allergy, health policy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
